Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression
出版年份 2020 全文链接
标题
Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 11, Pages 3907
出版商
MDPI AG
发表日期
2020-06-02
DOI
10.3390/ijms21113907
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SIRT3, PP2A and TTP protein stability in the presence of TNF‐α on vincristine‐induced apoptosis of leukaemia cells
- (2020) Liang‐Jun Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-κB signaling in esophageal squamous cell carcinoma
- (2019) Jiali Tao et al. OncoTargets and Therapy
- Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477
- (2019) David J. Mallick et al. Cell Death & Disease
- SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation
- (2019) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
- (2019) Guerini et al. Cancers
- ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells
- (2018) Yuan-Chin Lee et al. CANCER LETTERS
- Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
- (2018) Eunhye Oh et al. INTERNATIONAL JOURNAL OF CANCER
- Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton
- (2018) Michel O. Steinmetz et al. TRENDS IN CELL BIOLOGY
- Mebendazole potentiates radiation therapy in triple-negative breast cancer
- (2018) Le Zhang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells
- (2018) Ying-Jung Chen et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-α upregulation
- (2018) Liang-Jun Wang et al. BIOCHEMICAL PHARMACOLOGY
- BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
- (2018) Delphine Merino et al. CANCER CELL
- Microtubule destabilising agents: far more than just antimitotic anticancer drugs
- (2016) Darcy Bates et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Albendazole as a promising molecule for tumor control
- (2016) L.S.E.P.W. Castro et al. Redox Biology
- Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway
- (2015) Tongshuai Chen et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
- (2015) Lloyd T Lam et al. Cancer Cell International
- Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
- (2015) Fernando Torres et al. CURRENT MEDICINAL CHEMISTRY
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest
- (2015) Manuel D. Haschka et al. Nature Communications
- Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cell carcinoma cells
- (2014) Haidan Liu et al. BMC CANCER
- Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines
- (2014) YongKu Ryu et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
- (2014) Bin Wang et al. Molecular Cancer
- Targeting Microtubules by Natural Agents for Cancer Therapy
- (2014) E. Mukhtar et al. MOLECULAR CANCER THERAPEUTICS
- Mcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein
- (2014) Barbara Mojsa et al. Cells
- SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging
- (2012) Albert Giralt et al. BIOCHEMICAL JOURNAL
- Suppression of Akt/Foxp3-mediated miR-183 expression blocks Sp1-mediated ADAM17 expression and TNFα-mediated NFκB activation in piceatannol-treated human leukemia U937 cells
- (2012) Wen-Hsin Liu et al. BIOCHEMICAL PHARMACOLOGY
- Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS
- (2011) Yaohui Chen et al. EMBO REPORTS
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
- (2010) P. A. Spagnuolo et al. BLOOD
- Mcl-1; the molecular regulation of protein function
- (2010) Luke W. Thomas et al. FEBS LETTERS
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- SIRT3 Is a Stress-Responsive Deacetylase in Cardiomyocytes That Protects Cells from Stress-Mediated Cell Death by Deacetylation of Ku70
- (2008) N. R. Sundaresan et al. MOLECULAR AND CELLULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now